Investors interested in SME IPOs are closely tracking the Avience Biomedicals IPO GMP to estimate the company's expected listing performance. The Grey Market Premium (GMP) is an unofficial indicator that reflects investor demand before the shares are listed on the stock exchange.
In this article, we'll discuss the latest Avience Biomedicals IPO GMP, IPO details, issue price, allotment status, listing date, lot size, and whether investors should consider this SME IPO.
The Avience Biomedicals IPO GMP indicates the premium at which shares are trading in the unofficial grey market before listing.
Latest Avience Biomedicals IPO GMP: To be updated regularly based on grey market activity.
Expected Listing Price
Expected Listing Price = Issue Price + GMP
Since GMP changes daily, investors should track the latest updates before making any investment decisions.
Disclaimer: Grey Market Premium (GMP) is unofficial and should only be used as a market sentiment indicator. It does not guarantee listing gains or future stock performance.
Avience Biomedicals IPO Details
Avience Biomedicals IPO Lot Size
The minimum investment requirement for the IPO is as follows:
Since this is an SME IPO, investors should note the relatively higher investment requirement compared to mainboard IPOs.
Avience Biomedicals IPO Timeline
IPO Opening Date: 18 June 2026
IPO Closing Date: 22 June 2026
Basis of Allotment: 23 June 2026
Refund Initiation: 24 June 2026
Shares Credited to Demat: 24 June 2026
Tentative Listing Date: 25 June 2026
About Avience Biomedicals Limited
Avience Biomedicals Limited operates in the biomedical and healthcare sector. The company launched its SME IPO to raise ₹30.24 crore through an entirely fresh issue.
The funds raised through the IPO are expected to support business expansion, working capital requirements, and other corporate objectives as outlined in the company's offer documents.
Before investing, investors should review the company's financial statements, business model, competitive strengths, and potential risks.
Should You Apply for Avience Biomedicals IPO?
While evaluating the IPO, investors should consider the following factors:
Monitor the latest Avience Biomedicals IPO GMP to understand current market sentiment.
Review the company's revenue growth and profitability.
Compare its valuation with listed industry peers.
Assess the growth opportunities in the biomedical and healthcare sector.
Understand the risks associated with SME IPO investments.
Remember that GMP is only one indicator and should not be the sole basis for an investment decision.
Avience Biomedicals IPO GMP FAQs
What is the Avience Biomedicals IPO GMP today?
The Avience Biomedicals IPO GMP is updated regularly based on grey market trading activity before listing.
What is the final issue price of Avience Biomedicals IPO?
The IPO was priced at ₹208 per share.
When was the Avience Biomedicals IPO allotment finalized?
The IPO allotment was finalized on 23 June 2026.
When will Avience Biomedicals shares be listed?
The shares are scheduled for listing on the NSE SME platform on 25 June 2026 (tentative).
What is the minimum investment required for retail investors?
Retail investors were required to invest a minimum of ₹2,49,600 for 1,200 shares.
Final Thoughts
The Avience Biomedicals IPO GMP is an important indicator for investors looking to estimate the IPO's listing performance. However, GMP should always be considered alongside the company's financial performance, valuation, industry outlook, and long-term growth potential.
Stay tuned for the latest Avience Biomedicals IPO GMP, listing gains, subscription details, allotment updates, and post-listing performance.
Post a Comment